CBLI: AI 评分 50/100 — AI 分析 (4月 2026)

Cytocom, Inc. is a biopharmaceutical company focused on developing immunotherapies and radiation countermeasures. Their platform leverages Toll-like immune receptor activators to address unmet medical needs.

Key Facts: AI Score: 50/100 Sector: Healthcare

公司概况

概要：

Cytocom, Inc., a biopharmaceutical firm based in Buffalo, NY, specializes in immune system activation through Toll-like receptor technology. Their lead candidate, Entolimod, targets radiation injury and oncology, positioning them in the immunotherapy sector with potential applications across multiple serious medical conditions. The company also develops CBLB612, Mobilan and CBL0137.

CBLI是做什么的？

Cleveland BioLabs, Inc., now known as Cytocom, Inc., was founded with the mission of developing innovative approaches to address critical unmet medical needs by harnessing the power of the immune system. Headquartered in Buffalo, New York, the company focuses on researching and developing novel drugs that activate the immune system to combat diseases and mitigate the effects of radiation exposure. Their core technology platform revolves around Toll-like immune receptor activators, which have shown promise in both radiation injury mitigation and immuno-oncology applications. The company's most advanced product candidate is Entolimod, an immuno-stimulatory agent being developed as a radiation countermeasure and an immunotherapy for various oncology indications. Entolimod aims to protect against the harmful effects of radiation exposure and enhance the body's ability to fight cancer. In addition to Entolimod, Cytocom is also developing other products, including CBLB612, Mobilan, and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer. These product candidates represent Cytocom's commitment to advancing innovative therapies for a range of serious medical conditions. Currently, Cytocom employs 18 full-time employees.

CBLI的投资论点是什么？

Cytocom, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on Toll-like receptor activators for radiation countermeasures and immuno-oncology provides exposure to niche markets with significant growth potential. The primary value driver is the successful development and regulatory approval of Entolimod, their lead product candidate. Positive clinical trial results and subsequent FDA approval for either radiation mitigation or oncology indications could trigger a substantial increase in the company's market capitalization. However, the company's negative profit margin of -912.2% highlights the significant financial risks associated with drug development. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure additional funding to sustain operations through 2026 and beyond.

CBLI在哪个行业运营？

Cytocom, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant financial risks. The company's focus on immuno-oncology and radiation countermeasures aligns with growing market trends in personalized medicine and biodefense. The competitive landscape includes established pharmaceutical companies and smaller biotech firms, such as Catalyst Biosciences, Inc. (CATB), Celularity Inc. (CELU), CARGO Therapeutics, Inc. (CRGX), IN8bio, Inc. (INXB) and MACK. Success in this industry requires strong intellectual property, efficient clinical trial execution, and strategic partnerships.

Biotechnology

Healthcare

CBLI有哪些增长机遇？

Entolimod for Radiation Countermeasure: Cytocom is developing Entolimod as a radiation countermeasure, targeting a market driven by government stockpiling and biodefense initiatives. The market size is projected to reach billions of dollars, driven by increasing global security concerns. Securing a government contract for Entolimod could provide a significant revenue stream and validate the company's technology. Timeline for potential approval and commercialization is estimated within the next 3-5 years, pending successful clinical trials.
Entolimod for Oncology: Entolimod is also being investigated as an immunotherapy for various oncology indications. The immuno-oncology market is experiencing rapid growth, with a global market size projected to reach hundreds of billions of dollars by 2030. Positive clinical trial results in specific cancer types could lead to accelerated approval pathways and significant market penetration. Competition in this space is intense, requiring Cytocom to demonstrate superior efficacy and safety profiles.
CBLB612 Development: CBLB612, a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor, represents a potential growth opportunity for Cytocom. Further development and clinical trials could unlock its therapeutic potential in various inflammatory and autoimmune diseases. The market for TLR2/TLR6 agonists is growing, driven by increasing understanding of the role of innate immunity in disease pathogenesis. The timeline for commercialization depends on successful preclinical and clinical studies.
Mobilan for Immunotherapy: Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It represents another growth opportunity for Cytocom in the immunotherapy space. Development of Mobilan as a novel cancer therapy could attract partnerships and funding. The market for adenoviral-based therapies is expanding, driven by advancements in gene therapy and vaccine development. The timeline for commercialization depends on successful preclinical and clinical studies.
CBL0137 for Cancer Treatment: CBL0137, a small molecule with a multi-targeted mechanism of action, holds promise for treating various types of cancer. Further research and clinical trials could lead to its development as a novel cancer therapy. The market for small molecule cancer drugs remains significant, despite the rise of biologics. The timeline for commercialization depends on successful preclinical and clinical studies.

Market capitalization of $0.23 billion reflects investor valuation of Cytocom's pipeline and technology platform as of March 15, 2026.
Negative P/E ratio of -16.38 indicates that Cytocom is currently not profitable, typical for biotechnology companies in the development stage.
Gross margin of 100.0% suggests high potential profitability for approved products, but this is contingent on successful commercialization.
Profit margin of -912.2% highlights the significant expenses associated with research and development in the biopharmaceutical industry.
Beta of 0.68 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.

CBLI提供哪些产品和服务？

Develops drugs that activate the immune system.
Focuses on Toll-like immune receptor activators.
Creates radiation countermeasures.
Develops immunotherapies for oncology.
Researches and develops CBLB612.
Researches and develops Mobilan.
Researches and develops CBL0137.

CBLI如何赚钱？

Develops and patents novel drug candidates.
Conducts preclinical and clinical trials.
Seeks regulatory approval from agencies like the FDA.
Out-licenses or partners with larger pharmaceutical companies for commercialization.
Generates revenue through government contracts, licensing agreements, and product sales (if approved).

Government agencies (for radiation countermeasures).
Hospitals and oncology centers (for cancer therapies).
Patients with cancer and radiation exposure risks.
Pharmaceutical companies (through licensing agreements).

Proprietary Toll-like receptor technology platform.
Patent protection for drug candidates.
Expertise in radiation countermeasure development.
Established relationships with government agencies (potential).

什么因素可能推动CBLI股价上涨？

Upcoming: Clinical trial results for Entolimod in radiation mitigation.
Upcoming: Clinical trial results for Entolimod in oncology indications.
Upcoming: Potential government contracts for radiation countermeasures.
Ongoing: Advancements in Toll-like receptor technology platform.
Ongoing: Strategic partnerships with pharmaceutical companies.

CBLI的主要风险是什么？

Potential: Clinical trial failures for Entolimod.
Potential: Regulatory setbacks and delays.
Ongoing: Competition from established pharmaceutical companies.
Ongoing: Inability to secure additional funding.
Potential: Intellectual property challenges.

CBLI的核心优势是什么？

Proprietary Toll-like receptor technology.
Lead product candidate (Entolimod) in advanced development.
Potential for both radiation countermeasure and oncology applications.
Experienced management team.

CBLI的劣势是什么？

Significant financial losses and negative profit margin.
Dependence on successful clinical trial outcomes.
High regulatory hurdles and approval risks.
Limited commercialization experience.

CBLI有哪些机遇？

Government contracts for radiation countermeasures.
Partnerships with larger pharmaceutical companies.
Expansion into new therapeutic areas.
Accelerated approval pathways for orphan drug designations.

CBLI面临哪些威胁？

Competition from established pharmaceutical companies.
Clinical trial failures.
Regulatory setbacks.
Inability to secure additional funding.

CBLI的竞争对手是谁？

Catalyst Biosciences, Inc. — Focuses on hemostasis-related therapies. — (CATB)
Celularity Inc. — Develops cellular medicines from the postpartum placenta. — (CELU)
CARGO Therapeutics, Inc. — Focuses on cancer therapies. — (CRGX)
IN8bio, Inc. — Develops gamma-delta T cell therapies for cancer. — (INXB)
MACK — Unknown — (MACK)

Key Metrics

Volume: 0
MoonshotScore: 50/100

Company Profile

CEO: Yakov Kogan
Headquarters: Buffalo, US
Employees: 18
Founded: 2006

AI Insight

AI analysis pending for CBLI

常见问题

What does Cytocom, Inc. do?

Cytocom, Inc. is a biopharmaceutical company that focuses on developing and commercializing novel immunotherapies and radiation countermeasures. The company's core technology platform is based on Toll-like immune receptor activators, which stimulate the immune system to fight diseases and mitigate the effects of radiation exposure. Their lead product candidate, Entolimod, is being developed for both radiation mitigation and oncology indications. Cytocom aims to address unmet medical needs in these areas through innovative drug development.

What do analysts say about CBLI stock?

AI analysis is pending for CBLI. However, generally, biotechnology stocks are evaluated based on the potential of their drug pipeline, clinical trial results, and regulatory milestones. Key valuation metrics include market capitalization, cash burn rate, and potential revenue from future product sales. Growth considerations involve the successful development and commercialization of drug candidates, as well as the company's ability to secure funding and partnerships.

What are the main risks for CBLI?

The main risks for Cytocom, Inc. include clinical trial failures, regulatory setbacks, competition from established pharmaceutical companies, and the inability to secure additional funding. Clinical trial failures can significantly impact the company's valuation and future prospects. Regulatory setbacks can delay or prevent the approval of drug candidates. Competition from larger companies with greater resources poses a significant challenge. The company's financial losses and negative profit margin highlight the importance of securing additional funding to sustain operations.

What revenue streams does Cytocom, Inc. have in healthcare?

Currently, Cytocom, Inc. does not have established revenue streams as it is in the development stage. Potential future revenue streams include government contracts for radiation countermeasures, licensing agreements with pharmaceutical companies, and product sales upon regulatory approval of Entolimod or other drug candidates. The success of these revenue streams depends on the successful development, approval, and commercialization of their products.

How does Cytocom, Inc. navigate regulatory approval processes?

Cytocom, Inc. navigates regulatory approval processes by conducting preclinical and clinical trials to demonstrate the safety and efficacy of its drug candidates. The company works closely with regulatory agencies like the FDA to ensure compliance with regulatory requirements. They also seek accelerated approval pathways, such as orphan drug designations, for specific indications. Their regulatory strategy involves submitting comprehensive data packages and engaging in ongoing communication with regulatory agencies.

Is CBLI a good investment right now?

Use the AI score and analyst targets on this page to evaluate Cytocom, Inc. (CBLI). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for CBLI?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Cytocom, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find CBLI financial statements?

Cytocom, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.